Harmony Biosciences Holdings, Inc. Cash Flow Statement
HRMY / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
Harmony Biosciences Holdings, Inc. generated $348M in operating cash flow and $348M in free cash flow in FY2025. Free cash flow margin was 40.1% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Strong profit margin: 20.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | $158.7M | $145.5M | $128.9M | $181.5M | $34.6M | -$152.0M | -$152.0M |
| Depreciation & Amortization | - | $267.0K | $514.0K | - | $416.0K | $395.0K | $395.0K |
| Operating Cash Flow | $348.2M | $219.8M | $219.4M | $144.5M | $98.6M | -$75.4M | -$75.4M |
| Capital Expenditures | $310.0K | $1.2M | $312.0K | $172.0K | $298.0K | $149.0K | $149.0K |
| Free Cash Flow | $347.9M | $218.7M | $219.1M | $144.3M | $98.3M | -$75.6M | -$75.6M |
| Share Buybacks | - | - | $100.0M | - | - | $167.0K | - |
| FCF Margin | 40.1% | 30.6% | 37.6% | 33.0% | 32.2% | -1260.8% | - |